<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680823</url>
  </required_header>
  <id_info>
    <org_study_id>PRO08030283</org_study_id>
    <nct_id>NCT00680823</nct_id>
  </id_info>
  <brief_title>Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache</brief_title>
  <official_title>Is Paraspinal Intramuscular Ropivacaine Injection an Effective Treatment for Headache in a Pediatric Emergency Department?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Hickey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine if lower paracervical intramuscular ropivacaine injection is an
      effective treatment for pediatric headache in an emergency department setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methods: The study will be a double-blind randomized control trial. Patients will be randomly
      assigned to receive either intramuscular injection of the lower cervical paraspinous muscles
      with 1 mL of 0.5% ropivacaine on each side, placebo injections with 1 mL normal saline on
      each side, or no intervention at all. If randomized to an injection, the investigator and the
      patient will both be blinded as to the nature of the injection.

      The location of the child's pain as well as severity will be assessed immediately prior to
      intervention and every 10 minutes for 30 minutes. If after 30 minutes relief is insufficient
      for discharge to home, intravenous treatment will be instituted according to current
      protocol. Pain will be reassessed at the time of ultimate disposition. The scale used to
      assess severity will vary based on the child's age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Will be Pain Relief Sufficient for Discharge From the Emergency Department.</measure>
    <time_frame>30 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and Percent of Patients Admitted to the Hospital for Additional Therapy in Each Treatment Arm Based Upon Treating Clinicians Decision</measure>
    <time_frame>3 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-presentation to the Emergency Department With Headache Within 72 Hours of Participating in the Study</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Headache</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Ropivacaine Injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline Injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observation for 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
    <arm_group_label>Ropivacaine Injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
    <arm_group_label>Normal Saline Injections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chief complaint of headache

          -  Age 7-17 years

        Exclusion Criteria:

          -  Presence of fever

          -  meningismus

          -  headache that wakes the child at night

          -  known organic brain disease, mass, or tumor

          -  history of stroke

          -  history of allergy to ropivacaine or other aminoacyl local anesthetics

          -  history of liver disease

          -  history of impaired cardiac function

          -  abnormal neurologic signs

          -  a focal neurologic abnormality on exam that is not a known component of the child's
             headache syndrome

          -  cognitive inability to communicate the intensity of pain.

          -  history of shunt or other intracranial hardware
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Sieminski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2008</study_first_submitted>
  <study_first_submitted_qc>May 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2008</study_first_posted>
  <results_first_submitted>November 16, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Robert Hickey</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Headache</keyword>
  <keyword>Migraine</keyword>
  <keyword>Ropivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="P3">
          <title>Observation</title>
          <description>Observation for 30 minutes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="B3">
          <title>Observation</title>
          <description>Observation for 30 minutes.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14" spread="2"/>
                    <measurement group_id="B2" value="14" spread="2"/>
                    <measurement group_id="B3" value="15" spread="2"/>
                    <measurement group_id="B4" value="14" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Will be Pain Relief Sufficient for Discharge From the Emergency Department.</title>
        <time_frame>30 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>Observation for 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Will be Pain Relief Sufficient for Discharge From the Emergency Department.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number and Percent of Patients Admitted to the Hospital for Additional Therapy in Each Treatment Arm Based Upon Treating Clinicians Decision</title>
        <time_frame>3 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>Observation for 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percent of Patients Admitted to the Hospital for Additional Therapy in Each Treatment Arm Based Upon Treating Clinicians Decision</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Re-presentation to the Emergency Department With Headache Within 72 Hours of Participating in the Study</title>
        <time_frame>72 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline Injections</title>
            <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
          </group>
          <group group_id="O3">
            <title>Observation</title>
            <description>Observation for 30 minutes.</description>
          </group>
        </group_list>
        <measure>
          <title>Re-presentation to the Emergency Department With Headache Within 72 Hours of Participating in the Study</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of 0.5% ropivacaine on each side.
Ropivacaine: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline Injections</title>
          <description>Intramuscular injection of the lower cervical paraspinous muscles with 1.5 mL of normal saline on each side.
Normal saline: 1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.</description>
        </group>
        <group group_id="E3">
          <title>Observation</title>
          <description>Observation for 30 minutes.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain at injection site</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>neck pain at 3 days</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>neck pain at 1 month</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Hickey</name_or_title>
      <organization>Children's Hospital of Pittsburgh</organization>
      <phone>412 692 7692</phone>
      <email>robert.hickey@chp.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

